Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic

References

• WHO coronavirus (COVID-19) dashboard [Internet]. [2021 Mar 20]. Available from: https://covid19.who.int.
   Google Scholar
• Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.
   PubMed Web of Science ®Google Scholar
• Rizk JG, Kalantar-Zadeh K, Mehra MR, et al. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020;80(13):1267–1292.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Ingegnoli F, De Lucia O, et al. COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev. 2020;19(102523):102523.
   Google Scholar
• Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–2293.
   PubMed Web of Science ®Google Scholar
• Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5(1):e000935.
   PubMed Web of Science ®Google Scholar
• Caporali R, Caprioli M, Bobbio-Pallavicini F, et al. DMARDS and infections in rheumatoid arthritis. Autoimmun Rev. 2008;8(2):139–143.
   PubMed Web of Science ®Google Scholar
• Ye C, Cai S, Shen G, et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis. 2020;79(8):1007–1013.
   PubMed Web of Science ®Google Scholar
• Cheng C, Li C, Zhao T, et al. COVID-19 with rheumatic diseases: a report of 5 cases. Clin Rheumatol. 2020;39(7):2025–2029.
   PubMed Web of Science ®Google Scholar
• Hasseli R, Mueller-Ladner U, Hoyer BF, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7(1):e001464.
   PubMed Web of Science ®Google Scholar
• Favalli EG. Understanding the role of interleukin-6 (IL-6) in the joint and beyond: a comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatol Ther. 2020;7(3):473–516.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Ingegnoli F, Cimaz R, et al. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. 2020. cited 2020 Dec 28. Available from: https://ard.bmj.com/content/early/2020/05/22/annrheumdis-2020-217615
   Google Scholar
• Sarzi-Puttini P, Marotto D, Caporali R, et al. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: a multicentre retrospective study. J Autoimmun. 2020. 2020 Oct 20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506330/
   PubMed Web of Science ®Google Scholar
• Favalli EG, Agape E, Caporali R. Incidence and Clinical Course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol. 2020;47(8):1296.
   PubMed Web of Science ®Google Scholar
• The COVID-19 global rheumatology alliance global registry. [Internet]. [2020 Dec 28]. Available from: https://rheum-covid.org/updates/combined-data.html.
   Google Scholar
• Fredi M, Cavazzana I, Moschetti L, et al. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study. Lancet Rheumatol. 2020;2(9):e549–e556.
   PubMedGoogle Scholar
• Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases—Case series from New York. N Engl J Med. 2020;383(1):85–88.
   PubMed Web of Science ®Google Scholar
• Scirè CA, Carrara G, Zanetti A, et al. COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). Clin Exp Rheumatol. 2020;38(4):748–753.
   PubMed Web of Science ®Google Scholar
• Gianfrancesco M, Hyrich KL, Al-Adely S, et al., Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 79(7): 859–866. 2020.
   PubMed Web of Science ®Google Scholar
• D’Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot. Ann Rheum Dis. 2020;79(9):1156–1162.
   PubMed Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Rutherford AI, Subesinghe S, Hyrich KL, et al. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2018;77(6):905–910.
   PubMed Web of Science ®Google Scholar
• Barrett O, Abramovich E, Dreiher J, et al. Short- and long-term mortality due to sepsis in patients with rheumatoid arthritis. Rheumatol Int. 2017;37(6):1021–1026.
   PubMed Web of Science ®Google Scholar
• Kilian A, Chock YP, Huang IJ, et al., Acute respiratory viral adverse events during use of antirheumatic disease therapies: a scoping review. Semin Arthritis Rheum. 50(5): 1191–1201. 2020.
   PubMed Web of Science ®Google Scholar
• Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(10):1755–1766.
   PubMed Web of Science ®Google Scholar
• Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234–243.
   PubMed Web of Science ®Google Scholar
• Youssef J, Novosad S, Winthrop K. Infection Risk and Safety of Corticosteroid Use. Rheum Dis Clin North Am. 2016;42(1):157–176.
   PubMed Web of Science ®Google Scholar
• Fardet L, Petersen I, Nazareth I. Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med. 2016;13(5):e1002024.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Monti S, Ingegnoli F, et al. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheum. 2020;72(10):1600–1606.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Bugatti S, Klersy C, et al., Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther. 22(1): 290. 2020.
   PubMed Web of Science ®Google Scholar
• Ddf N, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(11):1393–1399.
   PubMed Web of Science ®Google Scholar
• Murray K, Quinn S, Turk M, et al. COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population. Rheumatology. 2020. cited 2020 Dec 30. Available from: https://doi.org/10.1093/rheumatology/keaa694
   Web of Science ®Google Scholar
• Bengtsson K, Jacobsson LTH, Rydberg B, et al. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study. BMC Musculoskelet Disord. 2016;17(1):499.
   PubMedGoogle Scholar
• Santos CS, Férnandez XC, Moriano Morales C, et al., Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe? RMD Open. 7(1): e001439. 2021.
   Web of Science ®Google Scholar
• Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2021;80(3):384–391.
   PubMed Web of Science ®Google Scholar
• Cassone G, Manfredi A, Vacchi C, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J Clin Med. 2020;9(4):1082.
   Web of Science ®Google Scholar
• Raimundo K, Solomon JJ, Olson AL, et al. Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J Rheumatol. 2019;46(4):360–369.
   PubMed Web of Science ®Google Scholar
• Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76(10):1700–1706.
   PubMed Web of Science ®Google Scholar
• Leuschner G, Behr J. Acute exacerbation in interstitial lung disease. Front Med (Lausanne). 2017;4:176.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
   PubMed Web of Science ®Google Scholar
• Huppert LA, Matthay MA, Ware LB. Pathogenesis of acute respiratory distress syndrome. Semin Respir Crit Care Med. 2019;40(1):31–39.
   PubMed Web of Science ®Google Scholar
• Vassiliou AG, Kotanidou A, Dimopoulou I, et al. Endothelial damage in acute respiratory distress syndrome. Int J Mol Sci. 2020;21. cited 2021 Mar 19. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699909/
   PubMed Web of Science ®Google Scholar
• McGonagle D, Sharif K, O’Regan A, et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6):102537.
   PubMed Web of Science ®Google Scholar
• Manfredi A, Cassone G, Furini F, et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J. 2020;50(9):1085–1090.
   PubMed Web of Science ®Google Scholar
• Otsuji N, Sugiyama K, Arifuku H, et al. Effect of tocilizumab on interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). Eur Resp J. 2020;56. cited 2021 Mar 20. Available from: https://erj.ersjournals.com/content/56/suppl_64/747
   Web of Science ®Google Scholar
• Roofeh D, Lin CJF, Goldin J, et al. Tocilizumab prevents progression of early systemic sclerosis associated interstitial lung disease. Arthritis Rheum. cited 2021 Mar 19;n/a. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41668
   Google Scholar
• Manfredi A, Luppi F, Cassone G, et al. Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia. Expert Rev Clin. 2020;16(8):751–770.
   PubMed Web of Science ®Google Scholar
• Samarpita S, Kim JY, Rasool MK, et al. Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug. Arthritis Res Ther. 2020;22(1):16.
   PubMed Web of Science ®Google Scholar
• Monnet E, Choy EH, McInnes I, et al. Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study. Ann Rheum Dis. 2020;79(3):316–323.
   PubMed Web of Science ®Google Scholar
• Esposito AJ, Menon AA, Ghosh AJ, et al. Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study. Am J Respir Crit Care Med. 2020;202(12):1710–1713.
   PubMed Web of Science ®Google Scholar
• Drake TM, Docherty AB, Harrison EM, et al. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. Am J Respir Crit Care Med. 2020;202(12):1656–1665.
   PubMed Web of Science ®Google Scholar
• Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851–858.
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Johnson SR, Fraenkel L, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3. Arthritis Rheum. 2021;73:e1–e12.
   Web of Science ®Google Scholar
• Advice for the public on COVID-19 – World Health Organization [Internet]. [cited 2020 Dec 31]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public.
   Google Scholar
• Accortt NA, Lesperance T, Liu M, et al. Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis. Arthritis Care Res. 2018;70(5):679–684.
   Web of Science ®Google Scholar
• Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785–791.
   PubMed Web of Science ®Google Scholar
• Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212(9):416–420.
   PubMed Web of Science ®Google Scholar
• Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group, HorbyP,et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020.
   Web of Science ®Google Scholar
• Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for COVID-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980.
   PubMed Web of Science ®Google Scholar
• Siemieniuk R, Rochwerg B, Agoritsas T, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379.
   PubMedGoogle Scholar
• Smolen JS, Rbm L, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699.
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Johnson SR, Fraenkel L, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1. Arthritis Rheum. 2020;72(8):1241–1251.
   PubMed Web of Science ®Google Scholar
• The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19 [Internet]. [cited 2020 Dec 31]. Available from: https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19.
   Google Scholar
• Zhao D, Zhang S, Igawa T, et al. Use of nonsteroidal anti-inflammatory drugs for COVID-19 infection: adjunct therapy? Cardiol Rev. 2020;28(6):303–307.
   PubMed Web of Science ®Google Scholar
• Fantini J, Di Scala C, Chahinian H, et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55(5):105960.
   PubMed Web of Science ®Google Scholar
• De Barros CM, Almeida Ca De F, Pereira B, et al. COVID-19 pandemic - A narrative review of the potential roles of chloroquine and hydroxychloroquine. Pain Physician. 2020;23(4S):S351–S366.
   PubMedGoogle Scholar
• Favalli EG, Lucia OD, Biggioggero M, et al. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients. Ann Rheum Dis. 2020 cited 2021 Jan 28; 218068. Available from: https://ard.bmj.com/content/early/2020/06/18/annrheumdis-2020-218068
   Google Scholar
• Jankelson L, Karam G, Becker ML, et al. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review. Heart Rhythm. 2020;17(9):1472–1479.
   PubMed Web of Science ®Google Scholar
• Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Keystone EC, Van Der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Biggioggero M, Maioli G, et al. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020;20(9):1012–1013.
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970–10975.
   PubMed Web of Science ®Google Scholar
• Biran N, Ip A, Ahn J, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. cited 2020 Sep 15. 2020;2(10):e603-e612. Available from.
   PubMedGoogle Scholar
• Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–e484.
   PubMedGoogle Scholar
• Furlow B. COVACTA trial raises questions about tocilizumab’s benefit in COVID-19. Lancet Rheumatol. cited 2020 Sep 15 2020;2(10):e592. Available from
   PubMedGoogle Scholar
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333–2344.
   PubMed Web of Science ®Google Scholar
• Caporali R, Favalli EG. Managing patients with rheumatic conditions during the COVID-19 pandemic. BMJ. 2020;369:m1633.
   PubMedGoogle Scholar
• Zhang Y, Wang J, Zhao L, et al. Online management of rheumatoid arthritis during COVID-19 pandemic. Ann Rheum Dis. 2021;80(1):e4–e4.
   PubMed Web of Science ®Google Scholar
• Costa L, Tasso M, Scotti N, et al. Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort. Ann Rheum Dis. 2020. cited 2021 Feb 1. Available from https://ard.bmj.com/content/early/2020/06/11/annrheumdis-2020-217806
   Google Scholar
• Cassione EB, Zanframundo G, Biglia A, et al. COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis. 2020;79(10):1382–1383.
   PubMed Web of Science ®Google Scholar
• Furer V, Rondaan C, Heijstek MW, et al., 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 79(1): 39–52. 2020.
   PubMed Web of Science ®Google Scholar
• Rondaan C, Furer V, Heijstek MW, et al., Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 5(2): e001035. 2019.
   PubMed Web of Science ®Google Scholar
• Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67(7):937–941.
   PubMed Web of Science ®Google Scholar
• Bingham CO, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62(1):64–74.
   PubMed Web of Science ®Google Scholar
• ACR-information-vaccination-against-SARS-CoV-2.pdf [Internet]. [cited 2021 Jan 1]. Available from: https://www.rheumatology.org/Portals/0/Files/ACR-Information-Vaccination-Against-SARS-CoV-2.pdf.
   Google Scholar
• EULAR | EULAR view-points on SARS-CoV-2 vaccination in patients with RMDs [Internet]. [cited 2021 Jan 1]. Available from: https://www.eular.org/eular_sars_cov_2_vaccination_rmd_patients.cfm.
   Google Scholar
• Houot R, Levy R, Cartron G, et al. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer. 2020;136:4–6.
   PubMed Web of Science ®Google Scholar
• Baker D, Roberts CAK, Pryce G, et al. COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases. Clin Exp Immunol. cited 2021 Feb 1. 2020;202:149–161. Available from. 2.
   Web of Science ®Google Scholar
• Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheum. 2016;68(1):56–66.
   PubMed Web of Science ®Google Scholar
• Schulze-Koops H, Krueger K, Vallbracht I, et al. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis. 2020 cited 2021 Feb 7; 218075. Available from: https://ard.bmj.com/content/early/2020/06/25/annrheumdis-2020-218075
   Web of Science ®Google Scholar
• Martínez-Sanz J, Muriel A, Ron R, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study. Clin Microbiol Infect. 2020. cited 2021 Feb 5. Available from: https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30573-5/abstract
   PubMed Web of Science ®Google Scholar
• Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020;38(3):529–532.
   PubMed Web of Science ®Google Scholar
• Tleyjeh IM, Kashour Z, Damlaj M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect. 2020 [cited 2021 Feb 5]. Available from: https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30690-X/abstract
   PubMed Web of Science ®Google Scholar
• Fiolet T, Guihur A, Rebeaud ME, et al. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(1):19–27.
   PubMed Web of Science ®Google Scholar
• Nguyen LS, Dolladille C, Drici M-D, et al. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization pharmacovigilance database. Circulation. 2020;142(3):303–305.
   PubMed Web of Science ®Google Scholar
• Chatre C, Roubille F, Vernhet H, et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41(10):919–931.
   PubMed Web of Science ®Google Scholar
• Tselios K, Deeb M, Gladman DD, et al. Antimalarial-induced cardiomyopathy: a systematic review of the literature. Lupus. 2018;27(4):591–599.
   PubMed Web of Science ®Google Scholar
• Lane JCE, Weaver J, Kostka K, et al., Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. 2(11): e698–e711. 2020.
   PubMedGoogle Scholar
• Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535–544.
   PubMed Web of Science ®Google Scholar
• Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313–319.
   PubMed Web of Science ®Google Scholar
• Carrat F, Lamballerie XD, Rahib D, et al. Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study. medRxiv. 2020;2020 sep 16.20195693.
   Google Scholar
• Indagine di sieroprevalenza sul SARS-CoV-2 [Internet]. 2020 [cited 2020 Sep 27]. Available from: https://www.istat.it/it/archivio/243340.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021 Feb 24 NEJMoa2101765. 10.1056/NEJMoa2101765.
   PubMedGoogle Scholar
• Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018;77(6):898–904.
   PubMed Web of Science ®Google Scholar
• Hua C, Barnetche T, Combe B, et al. Effect of methotrexate, anti–tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. 2014;66(7):1016–1026.
   PubMed Web of Science ®Google Scholar